Pharmacogenetic influence on bupropion bioactivation and clinical outcomes in major depressive disorder

Key Points

• Pharmacogenetic variations influence clinical outcomes of bupropion treatment in major depressive disorder.
• The study observed significant differences in bioactivation levels tied to specific genetic markers in participants.
• Observational analysis highlights how genetic factors shape responses to bupropion therapy for depression.
• Given these findings, individualized treatment plans may improve management of major depressive disorder.